Expect positive stock reaction on this first-line Phase III win. Monitor for regulatory submission in China and potential label expansion. The strong historical win rate (86% at T+20) on HCM supports a bullish read-through.
Price Chart
Executive Summary
HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) significantly improves progression-free survival vs TAGRISSO alone in first-line MET-overexpressing EGFR-mutated NSCLC in China. The combination also demonstrated encouraging overall survival benefit. This expands the clinical value of the all-oral combination into the first-line setting, building on prior SACHI and SAFFRON trials. The data will be submitted to regulatory authorities for label expansion in China.
Key Facts
- SANOVO Phase III met primary endpoint: statistically significant and clinically meaningful PFS improvement vs TAGRISSO alone in both high MET and ITT populations
- Encouraging OS benefit observed as secondary endpoint; trial continues follow-up
- Safety profile consistent with known profiles of each medicine; no new safety findings
- 326 treatment-naïve patients randomized 1:1 to ORPATHYS+TAGRISSO vs TAGRISSO+placebo
- ORPATHYS jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca
- ORPATHYS+TAGRISSO already approved in China for later-line MET-amplified EGFR-mutated NSCLC based on SACHI trial
Financial Impact
Potential label expansion into first-line NSCLC in China significantly expands addressable patient population for ORPATHYS+TAGRISSO combination; no specific revenue figures provided in filing
Risk Factors
- Regulatory approval for first-line indication not guaranteed; data review timeline uncertain
- Competition from other MET-targeted therapies and EGFR-TKI combinations
- OS data immature; final OS readout may differ from interim encouraging trend
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000055 |
| Document: hcm-20260831x6k.htm | 0001648257-26-000055 |
| Document: 0001648257-26-000055-index-headers.html | 0001648257-26-000055 |
| Document: 0001648257-26-000055-index.html | 0001648257-26-000055 |
| Document: 0001648257-26-000055.txt | 0001648257-26-000055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access